Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1624
This examiner grants 65% of resolved cases
Izabela Maria Schmidt is an examiner in Art Unit 1621 within Tech Center 1600. She has 101 resolved cases, with an allowance rate pct of 65.3. The median days to allowance is 1207, providing a standard timeline for prosecution. With 101 cases of historical data, the 65.3 allowance rate pct suggests a relatively favorable environment for applicants seeking a patent grant.
The interview lift pct of 42.5 is a substantial metric for practitioners. This high lift indicates that interviews are very effective at resolving rejections and moving cases toward allowance. Practitioners should prioritize direct communication to take advantage of the 42.5 lift, which significantly improves the baseline. The 1207-day median pendency is a key factor to consider when managing application timelines in this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17925776 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | Final Rejection | University of Florida Research Foundation, Inc. |
| 17789047 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | Final Rejection | New York University |
| 17766149 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18627081 | NOVEL KAPPA OPIOID LIGANDS | Non-Final OA | The Scripps Research Institute |
| 18585551 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | Non-Final OA | The University of Toledo |
| 18850362 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION | Non-Final OA | GH RESEARCH IRELAND LIMITED |
| 18572614 | CAPSAICIN AND TRPV1 MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | NOVAPANO, LLC |
| 18382636 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | Non-Final OA | MIRUM PHARMACEUTICALS, INC. |
| 17512451 | Benzylisoquinoline Alkaloids (BIA) Producing Microbes, and Methods of Making and Using the Same | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNOR UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy